In short
Clinical trials are studying Lorundrostat in people with hypertension, including uncontrolled and resistant hypertension. These studies look at long-term safety, tolerability, and how well Lorundrostat lowers blood pressure. Some trial parts also examine albuminuria, which means protein in the urine.
Key points
- Clinical trials of Lorundrostat are studying people with hypertension, including uncontrolled and resistant hypertension. Both studies are Phase 3 and focus on how well the treatment lowers blood pressure and how safe and tolerable it is. One trial is a main randomized, double-blind, placebo-controlled study, while the other is an open-label extension study for longer follow-up. The extension study also looks at blood pressure over time, treatment withdrawal, and albuminuria in some participants. Overall, the trial data focus on blood pressure control and longer-term follow-up in adults with hypertension.
Clinical trial overview
Two Phase 3 studies are listed for Lorundrostat, both focused on hypertension, which means high blood pressure. One study is a randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial, and the other is an open-label extension study. The trial records show that the main goals are to test efficacy, safety, and tolerability in people with uncontrolled or resistant hypertension.
Conditions being studied
The first study targets uncontrolled and resistant hypertension, meaning blood pressure that stays high despite treatment. The extension study includes subjects with hypertension and also looks at a subgroup with albuminuria, which means protein in the urine. This matters because the trial is not only looking at blood pressure, but also at a possible kidney-related marker in some participants.
Trial designs and phases
Both records describe Phase 3 research, which is a late stage of clinical testing. The main trial is randomized and double-blind, so participants are assigned to groups by chance and neither the participants nor the study team know who receives which treatment during the study period. It also uses placebo, which is a look-alike tablet without active study drug, to compare results fairly.
The extension study is open-label, which means the treatment is known to the participant and the research team. It is designed to follow people longer and assess whether the treatment effect lasts over time. The record also mentions a randomized treatment withdrawal substudy, which tests what happens when treatment is removed in a controlled way.
Who can participate
The studies include subjects with hypertension, especially those with uncontrolled or resistant hypertension. The extension study also includes people who were already enrolled in the parent studies, showing that some participants continue into longer follow-up. The trial data do not list every detailed eligibility rule, but they clearly focus on adults already living with difficult-to-control blood pressure.
Main outcomes being measured
The main outcome in the randomized Phase 3 study is the change in automated office blood pressure (AOBP) systolic blood pressure, or SBP, at Week 6 compared with baseline. Baseline means the starting point before the study treatment effect is measured. In simple terms, the study is asking whether Lorundrostat lowers the top blood pressure number more than placebo.
The extension study measures several blood pressure outcomes over time, including change from baseline to Week 12 and later follow-up points. It also measures the change in AOBP SBP in a randomized treatment withdrawal substudy, which helps show whether the blood pressure benefit continues when treatment is changed. Another outcome is the percent change in urine albumin creatinine ratio, or UACR, in participants who had albuminuria at the parent study baseline.
The extension study also focuses on long-term safety and tolerability. Safety means how well the treatment can be used without causing major harm, while tolerability means how well people can handle it overall. These outcomes are important because hypertension treatment often needs to be used for a long time.
What the trial data are trying to show
The trial records show that Lorundrostat is being studied as an add-on treatment for blood pressure control in people whose hypertension is hard to manage. The main question is whether it can improve systolic blood pressure compared with placebo and whether the effect lasts during longer follow-up. The extension study adds a second layer of research by looking at longer-term use, treatment withdrawal, and kidney-related markers such as albuminuria.
Because one study is completed and the extension study is authorised, the records suggest that Lorundrostat has already been tested in a major late-stage program for hypertension. The available data focus on whether the treatment can lower blood pressure, maintain that effect, and remain acceptable for longer use in the study population.